# China NMPA Drug Inspection - Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. - Dictamnus dasycarpus root bark

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/fb6feb9a-2734-48c6-a5c4-2a9aa8503e74/
Source feed: China

> China NMPA drug inspection for Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. published April 03, 2018. Drug: Dictamnus dasycarpus root bark. The Chongqing Municipal Food and Drug Administration (CMFDA) released its 2018 Issue 1 Drug Quality Announcement on Apri

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Food and Drug Administration's Drug Quality Bulletin, Issue 1, 2018
- Company Name: Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-04-03
- Drug Name: Dictamnus dasycarpus root bark
- Inspection Finding: [Characteristics] Does not meet the requirements.
- Action Taken: Public announcement of non-compliance
- Summary: The Chongqing Municipal Food and Drug Administration (CMFDA) released its 2018 Issue 1 Drug Quality Announcement on April 3, 2018, detailing findings from city-wide drug sampling inspections. The initiative aimed to bolster drug quality oversight, standardize market practices, and safeguard public health. The CMFDA identified twelve batches of drugs from multiple manufacturers that failed to meet quality standards.

Among the companies whose products were cited for non-compliance are Sichuan Longfa Pharmaceutical Co., Ltd., Sichuan Zhongyong Pharmaceutical Co., Ltd., Bozhou City Traditional Chinese Medicine Slices Factory, Anhui Haixin Traditional Chinese Medicine Pieces Co., Ltd., and Sichuan Gukang Traditional Chinese Medicine Pieces Co., Ltd. The violations spanned a range of critical issues, including failures in content determination (e.g., Abalone Shell, Magnolia Officinalis), non-conformity in physical properties or identification (e.g., Puhuang, Sandalwood), unsatisfactory appearance (e.g., Dictamnus dasycarpus root bark), and the presence of unacceptable residues like sulfur dioxide (Kudzu root). Some products also failed inspections for specific components such as magnesium or aluminum salts and total ash.

These assessments were conducted against the regulatory framework established by various editions of the Chinese Pharmacopoeia (2005, 2010, 2015) and supplementary testing methods from the State Food and Drug Administration. A notable aspect of the report indicated that some manufacturers denied producing the non-compliant drugs associated with their names. The announcement serves as a public notification, underscoring the CMFDA's commitment to continuous supervision and enforcement to ensure the safety and quality of pharmaceutical products available to the public.

Company: https://www.globalkeysolutions.net/companies/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/4f6f764d-7635-42f2-ab3f-4f79c6c03c0a/